Bone Biologics Corp reports results for the quarter ended March 31 - Earnings Summary

Bone Biologics

13/05/2025 17:00

Bone Biologics Corp BBLG.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.31.  The lone analyst forecast for the quarter was for a loss of 48 cents per share.

Reported revenue was zero​; analysts expected zero.

Bone Biologics Corp's reported EPS for the quarter was a loss of 32 cents​.

Bone Biologics Corp shares had fallen by 8.7% this quarter and lost 22.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

Wall Street's median 12-month price target for Bone Biologics Corp is $16.50

This summary was machine generated from LSEG data May 13 at 04:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.48
-0.32
Beat
Dec. 31 2024
-0.65
-0.61
Beat
Sep. 30 2024
-0.60
-2.37
Missed
Jun. 30 2024
-1.39
-0.67
Beat